DeLorean Artificial Intelligence

Name: DeLorean Artificial Intelligence
Brand: DeLorean Artificial Intelligence

Our flagship medical AI solution, MARTI, is the first #ai in the world to be biologically validated and saves $100PMPM

Est 2019|Valuation $59.5M|Raised $11.4M|4 Ref Customers

LinkedIn 8K|Website|FTEs 23|HQ Palm Beach, Florida, US

MarketsICP Analysis Sales Forecasting

DeLorean Artificial Intelligence screenshot

Published Oct 13, 2026

01Common complaints

- If publicly verifiable security documentation (for example, SOC 2 reports, ISO certificate numbers, or an accessible trust center) is a strict precondition for procurement. Public sources did not include these artifacts. - If the procurement decision requires extensive independent, high-volume user reviews to de-risk adoption. Public review coverage for the healthcare MARTI product is limited. - If the primary requirement is a broad, enterprise data platform and many operational applications delivered from a single vendor. Organizations seeking a one-stop platform with broad operational apps may prefer larger platform vendors. - If the organization is small or lacks internal data integration and clinical operations resources. Early-stage organizations without these capabilities may face long time-to-value and risk stalled programs. - Current limitations apparent from public materials - Public product pages do not enumerate limitations in detail; vendor messaging is primarily focused on capabilities and outcomes. - Roadmap items and availability - Some vendor pages referenced planned modules and release timelines; the current availability status for some modules should be confirmed with the vendor directly. - Scale limitations and claims requiring validation - Vendor claims such as modeling tens of millions of patients or conducting whole-population (no sampling) modeling are substantial and should be validated via architecture, scalability tests, and performance benchmarks prior to procurement. - Security and compliance gaps - The absence of publicly documented SOC 2/ISO artifacts and published security documentation represents a procurement risk for regulated buyers. - API and integration constraints - No public API documentation was located; integration approaches are likely to require professional services unless APIs and integration guides are provided during technical diligence.

Deal disqualifiers: what makes a poor fit

Organizations with low data maturity or highly fragmented systems, teams expecting a plug-and-play deployment without workflow change management, or organizations that require publicly available security certifications before engaging with a vendor.

02Why they buy

- Competitive advantages supported by semi-independent signals - Independent reporting documents that at least one real-world lab evaluated the system in a proof-of-concept and that the product provides recommended actions paired with risk predictions. This is an operational signal beyond vendor marketing. - Product capabilities that the vendor emphasizes - On-premises deployment option for organizations that need to maintain data control. - Packaged disease modules and a combined prediction-plus-recommendation approach. - Areas where competitors have advantages - Competitors may provide broader platform breadth, larger installation bases, more published case studies, and more publicly available enterprise documentation and certifications.

03Field reports

Important context about review availability

Traditional B2B review platforms (G2, Gartner Peer Insights, TrustRadius) show limited or no publicly accessible independent end-user reviews for DeLorean AI’s MARTI product.
Vendor/product pages exist for DeLorean AI CRM AI on review sites, but independent end-user reviews for the healthcare MARTI product are scarce.

Voice-of-customer signals (with limitations)

- Partner and vendor-authored statements - Partner and vendor materials describe using DeLorean AI models for risk stratification and recommending actions; these should be treated as partner-supplied content rather than independent evaluations. - Independent reporting - Independent reporting about a proof-of-concept and early evaluation raises adoption questions, specifically clinician acceptance of recommendations and the importance of careful feature selection and data quality for model performance. - Workforce/employee comments - Public employee review platforms show very small, non-representative samples tied to the brand, and they do not constitute product reviews. These samples are insufficient to generalize.

Community / social signals

Brand-specific discussions were not prominent on public forums. Broader community sentiment about AI in CRM contexts generally expresses skepticism that AI insights change behavior without high-quality CRM data and integrated workflows.

Positive vs negative signal balance (what’s missing)

Positive signals are primarily vendor claims, partner whitepapers, and press releases.
Negative signals or concerns are primarily independent reporting about adoption and validation challenges and general community skepticism about CRM AI effectiveness.
A major limitation is the lack of accessible, high-volume independent end-user review data for MARTI.

Case study 1: Renal care pilot (vendor white paper) — multi-center short-term pilot

- Source and design - A vendor-published white paper describes a pilot of DeLorean AI’s Medical AI conducted across multiple dialysis centers over a brief pilot period. - Reported outcomes (as described in vendor-authored materials) - The white paper reports that the AI predicted missed treatments and hospitalizations related to fluid overload and supported other measures used for care planning and retrospective quality improvement analyses. - Critical evaluation - The material is vendor- and partner-produced; methodology details (for example, controls, statistical adjustments, and baseline comparisons) are not fully visible in the available excerpts. - Procurement and clinical governance teams should request detailed study design documents, endpoints, baseline rates, variance measures, how recommended actions were operationalized, and independent validation where available.

Case study 2: Ascend Clinical + platform partner (press and independent reporting)

- What happened - Press materials describe Ascend Clinical evaluating DeLorean AI’s renal model on a third-party AI compute platform; the solution ingested structured and unstructured data (medical records, labs, claims) for risk prediction and recommended actions, and was described as commercially licensed with cloud or on-premises deployment options. - Independent reporting added that the evaluation included a proof-of-concept, that a commercial license was obtained during evaluation, and that clinician comfort with recommendations remained an open question at the time of reporting. - Critical evaluation - Press release language included claims difficult to verify without corroborating documentation. - Independent reporting that describes evaluation work and adoption questions is a practical signal for buyers because it documents real-world integration and validation steps and highlights the need for clinical validation and governance.

Case study 3: Cardiovascular model (vendor press release)

- Claimed results - A vendor press release reported retrospective analyses and stated performance metrics and cost reduction estimates. - Critical evaluation - The material was distributed via press channels and includes vendor claims; buyers should request the full white paper, detailed performance evaluation methods, independent validation, and subgroup analyses to assess applicability and potential demographic performance differences.

04Best fit

Company sizes

Best fit appears to be organizations large enough to maintain claims/EHR/lab feeds and to have care management staff and clinical governance capacity.
Practical ICP range (inferred):
- Payers: regional to national plans covering large populations.
- Provider networks/ACOs: multi-clinic groups with chronic disease programs.
- Dialysis networks: operators managing multiple centers.

Industries and verticals where adoption is strongest (with customer examples)

Dialysis and renal care (vendor and partner materials describe pilots and deployments in dialysis networks and related labs).

Roles and personas

Decision makers: Chief Medical Officers, VPs of Population Health, Chief Nursing Officers, payer medical directors, and CIO/CTO/data platform leads.
End users: care managers, nurses, social workers, nephrologists (based on pilot descriptions).

Pain points and challenges the product addresses

Identifying avoidable hospitalizations, missed treatments, and progression to high-cost disease states; supporting operational decisions in clinic contexts.

Qualification criteria: what makes a suitable fit

Consistent data capture (treatment, labs, EHR integration), the ability to operationalize recommended actions into care pathways, and willingness to support clinical governance and validation.

05The pitch

What the product does (core value proposition in objective terms)

- DeLorean Artificial Intelligence (DeLorean AI / DAI) offers predictive AI products aimed at: - Healthcare payers and providers: predicting disease onset/progression and near-term adverse events (for example, hospitalization risk), plus "next best action" recommendations via its Medical AI product branded MARTI (Medical • Artificial • Real • Time • Intelligence). - Sales/RevOps teams (separate line): CRM AI that predicts deal outcomes (win/loss, stage of pipeline failure) and provides recommended actions. - In practice, the company positions MARTI as a population-scale predictive and risk-stratification layer with recommended interventions that can be integrated into existing analytics tools (PowerBI/Tableau) and deployed in different hosting environments (on-premises or public cloud).

Target market and market positioning

Primary positioning is B2B healthcare (payers, at‑risk providers, dialysis networks, care management organizations) focused on chronic disease management (renal, diabetes, cardiac, behavioral health, respiratory).
Secondary positioning is enterprise pipeline intelligence for sales organizations via CRM AI.

Get a comprehensive analysis of DeLorean Artificial Intelligence including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →